AVP
About AVP
AXA Venture Partners; led Deepgram's Series C.
AVP began as the venture arm of AXA. Sources give 2015 or 2016 as the start. It later completed a management buyout from AXA and rebranded as Atlantic Vantage Point (AVP), now an independent firm. AXA stays a strategic partner, and AXA Deputy CEO George Stansfield chairs AVP's board. François Robinet is named as managing partner. Elizabeth de Saint-Aignan, a partner, has spoken publicly about the Deepgram investment and the firm's view of enterprise voice AI. AVP has not published a list of partners dedicated to AI.
AVP describes itself as a specialist growth investor that offers AI founders AI expertise, global networks and long-term capital. Its Deepgram write-up argues that human interaction with AI is shifting from text to voice. It names both foundation models and an enterprise layer (deployment, tooling, reliability, security) as the markers of leadership. In the Deepgram announcement, AVP was cited for experience scaling category-defining companies and for helping with expansion into Europe. Its portfolio also includes AI-linked healthcare companies. The Lounge deals desk lists a second lead, WhiteLab Genomics' Series B.
AVP invests across four strategies: venture, early growth, growth and fund of funds. It manages more than €2.5 billion. Its Growth Fund I is €1.5 billion, and the European Investment Fund joined AXA as an anchor investor through the European Tech Champions Initiative. That fund's early deals included Agicap and Odoo. AVP has not published a check size range. Its two AI leads on Lounge are a $130M Series C and a $26M Series B, where AVP led the round and its own share is not disclosed.
- Deepgram: real-time voice AI platform; AVP led its $130M Series C announced January 2026, reported at a $1.3B valuation.
- WhiteLab Genomics: AVP led its $26M Series B (2026-10, per the Lounge deals desk).
- Troy Medicare: US healthcare company offering AI-driven Medicare plans; listed as an AVP portfolio company in press coverage (round and year not stated).
- siliconcanals.com/axa-venture-partners-rebrands-eif-joins-investor
- globalventuring.com/corporate/corporate-venturer/avp-axas-cvc-goes-ind
- coverager.com/avp-rebrands-following-mbo
- deepgram.com/learn/press-release-deepgram-raises-series-c
- avpcap.com/why-we-invested-in-deepgram
- cryptorank.io/news/feed/30ba1-deepgram-130m-series-c-voice-ai-acquisit
Investing activity
AVP appears in 2 AI deals tracked by the AI Lounge deals desk, rounds totalling $156M, and led 2 of them. The rounds are mostly Series B and Series C, with a median round size of $130M. The most recent are WhiteLab Genomics (Series B, $26M, Oct 2026) and Deepgram (Series C, $130M, Jan 2026).
AVP most often invests alongside Debiopharm Innovation Fund, Omnes Capital, Blast Club and Yaday Health, and the companies it backs on AI Lounge are mostly in AI biotech / genomic medicine and Voice AI.
Deals
Frequently asked questions about AVP
Does AVP invest in AI startups?
Yes. AVP led Deepgram's $130M Series C in January 2026 and, per the Lounge deals desk, WhiteLab Genomics' $26M Series B. It describes itself as a growth investor that offers AI founders deep AI expertise.
What stage does AVP invest at?
AVP runs venture, early growth and growth strategies, plus fund of funds. Its recent AI leads were Series B and Series C rounds.
How big are AVP's funds?
AVP manages more than €2.5 billion in total. Its Growth Fund I is €1.5 billion, and the European Investment Fund is an anchor investor in it.
What is the AVP check size for AI companies?
AVP has not published a check size range. Round sizes it has led include $26M and $130M, but its own share of each is not disclosed.
Is AVP the same firm as AXA Venture Partners?
Yes. AXA Venture Partners completed a management buyout from AXA and rebranded as AVP, short for Atlantic Vantage Point. AXA remains a strategic partner.
What AI companies has AVP invested in?
AVP's AI investments include WhiteLab Genomics and Deepgram. The 2 rounds on AI Lounge are listed on this page with amounts, dates and co-investors.
Where is AVP based?
AVP is based in Paris, France.
Who does AVP co-invest with?
AVP's most frequent co-investors on AI Lounge are Debiopharm Innovation Fund (1 deal), Omnes Capital (1 deal), Blast Club (1 deal), Yaday Health (1 deal) and ServiceNow Ventures (1 deal).
How can founders reach AVP?
Founders on AI Lounge can see AVP's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with the firm under Warm Paths, and add AVP to their Investor Pipeline to track the conversation.